BioMarin Pharma Reports FDA's Clinical Hold On BMN 307 Phearless Phase 1/2 Study
6/9 08:26
(RTTNews) - Based on interim safety findings from a pre-clinical, non-GLP pharmacology study, FDA has placed a clinical hold on the BMN 307 Phearless Phase 1/2 study, BioMarin Pharmaceutical Inc. (BMRN) said. The study is evaluating BMN 307, an investigational AAV5-phenylalanine...